Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: amyotrophic lateral sclerosis therapy - ALS Therapy Development Institute

Next Previous
Search
Drug Profile

Research programme: amyotrophic lateral sclerosis therapy - ALS Therapy Development Institute

Alternative Names: ALS TDI 00846; TDI 104; TDI 142; TDI 158; TDI 163; TDI 168; TDI 186; TDI 197; TDI 201; TDI 202; TDI 206; TDI 207; TDI 208; TDI 209; TDI 210; TDI 211; TDI 28; TDI 53

Latest Information Update: 07 Jan 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALS Therapy Development Institute
  • Class Antisense oligonucleotides; Small molecules
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
  • 14 Sep 2020 Anelixis Therapeutics has been acquired and merged into Novus Therapeutics
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top